Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Melphalan, and Bendamustine for ASCT in Multiple Myeloma
NCT02148913Phase 1Completed
- Sponsor
- Corewell Health
- Start
- Jun 2014
- Primary completion
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of carfilzomib in multiple myeloma (MM) (4 cohorts), sponsored by Corewell Health. Primary endpoint: Absence of Dose Limiting Toxicity at 90 days. Started Jun 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02148913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148913.